Overview
Superficial epidermolytic ichthyosis (SEI), also known as ichthyosis bullosa of Siemens (IBS), is a rare genetic skin disorder characterized by superficial blistering and hyperkeratosis (thickening of the outer layer of the skin). It is caused by mutations in the KRT2 gene (keratin 2), which encodes a protein expressed in the upper layers of the epidermis (suprabasal keratinocytes of the granular layer). Because the defective keratin is expressed more superficially in the skin compared to classic epidermolytic ichthyosis, the blistering in SEI tends to be milder and more superficial, with characteristic "mauserung" — a distinctive shedding or molting phenomenon where sheets of superficial skin peel off, particularly over the limbs. Clinical features typically present at birth or in early infancy with episodes of skin fragility, superficial blistering, and peeling. Over time, the blistering tendency may decrease while mild to moderate dark (hyperkeratotic) scaling develops, predominantly affecting the limbs, particularly the shins and flexural areas. The palms and soles are generally spared. The condition is generally milder than classic epidermolytic ichthyosis (caused by KRT1 or KRT10 mutations), and widespread erythroderma is typically absent. Histologically, the skin shows epidermolytic hyperkeratosis confined to the granular and upper spinous layers. There is no cure for superficial epidermolytic ichthyosis. Treatment is symptomatic and supportive, focusing on skin care with regular use of emollients and keratolytic agents (such as urea-based or lactic acid-based creams) to reduce scaling and improve skin texture. Avoidance of excessive heat and friction can help minimize blistering episodes. Retinoids may be considered in more severe cases but must be used cautiously due to potential side effects. Genetic counseling is recommended for affected individuals and their families.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Superficial epidermolytic ichthyosis.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Superficial epidermolytic ichthyosis at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Superficial epidermolytic ichthyosis.
Community
No community posts yet. Be the first to share your experience with Superficial epidermolytic ichthyosis.
Start the conversation →Latest news about Superficial epidermolytic ichthyosis
No recent news articles for Superficial epidermolytic ichthyosis.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Superficial epidermolytic ichthyosis
What is Superficial epidermolytic ichthyosis?
Superficial epidermolytic ichthyosis (SEI), also known as ichthyosis bullosa of Siemens (IBS), is a rare genetic skin disorder characterized by superficial blistering and hyperkeratosis (thickening of the outer layer of the skin). It is caused by mutations in the KRT2 gene (keratin 2), which encodes a protein expressed in the upper layers of the epidermis (suprabasal keratinocytes of the granular layer). Because the defective keratin is expressed more superficially in the skin compared to classic epidermolytic ichthyosis, the blistering in SEI tends to be milder and more superficial, with char
How is Superficial epidermolytic ichthyosis inherited?
Superficial epidermolytic ichthyosis follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Superficial epidermolytic ichthyosis typically begin?
Typical onset of Superficial epidermolytic ichthyosis is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Superficial epidermolytic ichthyosis?
15 specialists and care centers treating Superficial epidermolytic ichthyosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.